• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ten Stocks Trending on Discord for Monday August 22, 2022: AMC, GBNH, BBBY, NEPT, SMMT, AVYA, ANPC, APRN, DNAA, KRBP

    8/22/22 11:51:51 AM ET
    $AMC
    $ANPC
    $APRN
    $AVYA
    Movies/Entertainment
    Consumer Discretionary
    Medical Specialities
    Health Care
    Get the next $AMC alert in real time by email
    Get the next $AMC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMC
    $ANPC
    $APRN
    $AVYA

    CompanyDatePrice TargetRatingAnalyst
    Summit Therapeutics Inc.
    $SMMT
    3/16/2026$15.00Buy → Hold
    Jefferies
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    Summit Therapeutics Inc.
    $SMMT
    9/17/2025$13.00Underweight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    9/4/2025$40.00Buy
    Guggenheim
    Summit Therapeutics Inc.
    $SMMT
    8/19/2025$21.00Neutral
    Piper Sandler
    AMC Entertainment Holdings Inc.
    $AMC
    7/11/2025$4.00Neutral → Outperform
    Wedbush
    Summit Therapeutics Inc.
    $SMMT
    7/1/2025$30.00Buy
    UBS
    More analyst ratings

    $AMC
    $ANPC
    $APRN
    $AVYA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tabacco Joseph J Jr bought $102,200 worth of shares (20,000 units at $5.11) (SEC Form 4)

    4 - BED BATH & BEYOND, INC. (0001130713) (Issuer)

    3/12/26 8:32:43 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Director Xia Yu bought $9,999,983 worth of shares (533,617 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 9:06:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $499,983 worth of shares (26,680 units at $18.74) and was granted 14,247,597 shares, increasing direct ownership by 3% to 570,073,879 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 4:08:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMC
    $ANPC
    $APRN
    $AVYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dubois Lisa Foley

    4 - BED BATH & BEYOND, INC. (0001130713) (Issuer)

    4/6/26 4:19:10 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 3 filed by new insider Dubois Lisa Foley

    3 - BED BATH & BEYOND, INC. (0001130713) (Issuer)

    4/6/26 4:16:41 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 4 filed by Sullivan Amy Ervin

    4 - BED BATH & BEYOND, INC. (0001130713) (Issuer)

    4/6/26 4:13:14 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMC
    $ANPC
    $APRN
    $AVYA
    SEC Filings

    View All

    SEC Form PRE 14A filed by Summit Therapeutics Inc.

    PRE 14A - Summit Therapeutics Inc. (0001599298) (Filer)

    4/6/26 4:28:53 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bed Bath & Beyond Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

    8-K - BED BATH & BEYOND, INC. (0001130713) (Filer)

    4/2/26 4:05:31 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Bed Bath & Beyond Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BED BATH & BEYOND, INC. (0001130713) (Filer)

    4/2/26 8:28:18 AM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMC
    $ANPC
    $APRN
    $AVYA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bed Bath & Beyond, Inc. Scheduled to Release First Quarter 2026 Financial Results

    Bed Bath & Beyond, Inc. (NYSE:BBBY) (the "Company"), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's Home, and a blockchain asset portfolio, today announced that it is scheduled to release first quarter 2026 financial results after the market closes on Monday, April 27, 2026. The Company has also scheduled a conference call and webcast to be held on Monday, April 27, 2026, at 4:30pm ET to discuss these results and take questions from participants during the live event. Questions may also be submitted to [email protected] in advance. Webcast and Replay Information To access the live webcast, visit investors.beyond.com. To participate in the conference call via telephone, ple

    4/6/26 4:01:00 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Bed Bath & Beyond Names Veteran Retail Operator Amy Sullivan President

    Bed Bath & Beyond, Inc. (NYSE:BBBY) ("Bed Bath & Beyond" or the "Company"), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's, and a blockchain asset portfolio, today announced the appointment of Amy Sullivan as President, effective immediately, as the Company accelerates its next phase of disciplined growth. Sullivan is a merchant and operator who built her career across some of retail's most recognized brands, including JCPenney, Kohl's, Lands' End, Express, and Lane Bryant, before joining Kirkland's in 2012, where she rose from divisional merchandise manager to President and CEO. As CEO of The Brand House Collective, the operating entity she led through its transformation

    4/6/26 8:30:00 AM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    AMC Entertainment Delivers Best Ever Global Revenue Mark for a 5-Day Easter Weekend, Led by THE SUPER MARIO GALAXY MOVIE, Strong Merchandise Sales, and Solid Performances by Other Titles

    Led by a media-reported global box office debut of $372 million for THE SUPER MARIO GALAXY MOVIE, AMC Entertainment posted its largest combined global admissions and food & beverage revenue for a 5-day Easter weekend in the Company's 106-year history More than 6.0 million moviegoers attended AMC Theatres in the United States or ODEON Cinemas internationally from Wednesday, April 1 through Sunday, April 5; this was also AMC's highest global attendance for Wednesday through Sunday in 2026 AMC's merchandise program for THE SUPER MARIO GALAXY MOVIE was a major hit with moviegoers and ranks as AMC's second-best selling and second-highest grossing merchandise program of all time, behind only

    4/6/26 8:20:00 AM ET
    $AMC
    Movies/Entertainment
    Consumer Discretionary

    $AMC
    $ANPC
    $APRN
    $AVYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Summit Therapeutics downgraded by Jefferies with a new price target

    Jefferies downgraded Summit Therapeutics from Buy to Hold and set a new price target of $15.00

    3/16/26 8:36:55 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Summit Therapeutics from Underweight to Equal Weight and set a new price target of $18.00

    12/17/25 8:48:06 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Summit Therapeutics

    Wolfe Research initiated coverage of Summit Therapeutics with a rating of Peer Perform

    11/18/25 8:28:20 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMC
    $ANPC
    $APRN
    $AVYA
    Leadership Updates

    Live Leadership Updates

    View All

    Bed Bath & Beyond Names Veteran Retail Operator Amy Sullivan President

    Bed Bath & Beyond, Inc. (NYSE:BBBY) ("Bed Bath & Beyond" or the "Company"), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's, and a blockchain asset portfolio, today announced the appointment of Amy Sullivan as President, effective immediately, as the Company accelerates its next phase of disciplined growth. Sullivan is a merchant and operator who built her career across some of retail's most recognized brands, including JCPenney, Kohl's, Lands' End, Express, and Lane Bryant, before joining Kirkland's in 2012, where she rose from divisional merchandise manager to President and CEO. As CEO of The Brand House Collective, the operating entity she led through its transformation

    4/6/26 8:30:00 AM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Groupon Launches Board-Level Artificial Intelligence Committee and Appoints Amit Shah to Board of Directors

    Technology executive and AI entrepreneur to chair new committee as Company positions marketplace for the era of agentic commerceChicago, Illinois--(Newsfile Corp. - March 10, 2026) - Groupon, Inc. (NASDAQ:GRPN) today announced the appointment of Amit Shah to its Board of Directors, effective March 10, 2026, and the formation of a dedicated Artificial Intelligence Committee of the Board. Shah, a seasoned technology executive and AI entrepreneur, will serve as the Committee's inaugural Chair.With this action, Groupon becomes one of the first publicly traded consumer marketplaces to establish a board-level committee dedicated to artificial intelligence. The formation of the Committee reflects t

    3/10/26 4:15:00 PM ET
    $APRN
    $FLWS
    $GRPN
    Catalog/Specialty Distribution
    Consumer Discretionary
    Other Specialty Stores
    Advertising

    LAIKA Partners With Fathom Entertainment for Domestic Distribution and FilmNation Entertainment for International Sales on Wildwood

    Confirms October 23, 2026 U.S. Release Date LAIKA, the studio behind Coraline and ParaNorman, announced today that it has partnered with Fathom Entertainment for U.S. theatrical distribution and FilmNation Entertainment for international sales on its upcoming stop-motion feature film Wildwood. The film will open in theaters nationwide on October 23, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120938376/en/LAIKA Names Fathom Entertainment as US Distributor and FilmNation Entertainment for International Sales for "Wildwood" coming October 23, 2026 The announcement reflects a new phase for LAIKA, as the studio expands

    1/20/26 11:15:00 AM ET
    $AMC
    $CNK
    Movies/Entertainment
    Consumer Discretionary

    $AMC
    $ANPC
    $APRN
    $AVYA
    Financials

    Live finance-specific insights

    View All

    Bed Bath & Beyond, Inc. Scheduled to Release First Quarter 2026 Financial Results

    Bed Bath & Beyond, Inc. (NYSE:BBBY) (the "Company"), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's Home, and a blockchain asset portfolio, today announced that it is scheduled to release first quarter 2026 financial results after the market closes on Monday, April 27, 2026. The Company has also scheduled a conference call and webcast to be held on Monday, April 27, 2026, at 4:30pm ET to discuss these results and take questions from participants during the live event. Questions may also be submitted to [email protected] in advance. Webcast and Replay Information To access the live webcast, visit investors.beyond.com. To participate in the conference call via telephone, ple

    4/6/26 4:01:00 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    National CineMedia, Inc. Reports Results for Fiscal Fourth Quarter and Full Year 2025

    Fourth quarter operating income increases year-over-year and fourth quarter adjusted OIBDA exceeds guidance Fourth quarter revenue growth of 8% outpaced attendance as NCM attracted greater advertiser demand National CineMedia, Inc. (NASDAQ:NCMI) (the "Company" or "NCM"), the managing member of National CineMedia, LLC (NCM LLC), the operator of the largest cinema advertising platform in the U.S., announced today its consolidated results for the fiscal fourth quarter and year ended January 1, 2026. "NCM expanded fourth quarter revenue by 8% year-over-year, demonstrating the returns from our continued investment in our platform over the course of the year," said Tom Lesinski, Chief Execu

    2/26/26 4:05:00 PM ET
    $AMC
    $CNK
    $NCMI
    Movies/Entertainment
    Consumer Discretionary
    Advertising

    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

    HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026 US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026 First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors GSK Collaboration Clinical Trials Evaluating Ivonescimab in

    2/23/26 4:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMC
    $ANPC
    $APRN
    $AVYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kiromic BioPharma Inc.

    SC 13G/A - Kiromic Biopharma, Inc. (0001792581) (Subject)

    11/4/24 7:38:30 PM ET
    $KRBP
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Summit Therapeutics Inc.

    SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

    9/13/24 5:54:25 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by AMC Entertainment Holdings Inc.

    SC 13G - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Subject)

    8/1/24 9:57:11 PM ET
    $AMC
    Movies/Entertainment
    Consumer Discretionary